Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B
Status:
Unknown status
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
For HBeAg(+) patients, interferon is used for 12 weeks. On 12th week of treatment, If HBV DNA
is undetectable (<1000 copies/ml), interferon is continued alone for one year. If HBV DNA is
still positive, nucleoside analogue is added for 3 months. After nucleoside analogue is added
for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use
interferon alone for another 6 months or longer. If HBV DNA is still positive, change to
another nucleoside analogue or add another nucleoside analogue.